Abstract
Developing drugs to treat atherosclerosis is a daunting task. However, recent studies of advanced human atherosclerotic lesions have yielded new information on potential mechanisms of inflammation and immune responses in late-stage human atherosclerosis. As leukotrienes (LTs) are among the most powerful inflammatory mediators known and because the 5-lipoxygenase pathway is expressed in diseased arteries, the roles of LTs in atherogenesis merit consideration. It is also of interest to consider pharmacological strategies to develop anti-LT drugs in atherogenesis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
